Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 522,000, an increase of 100.0% compared to RMB 261,000 in 2024[3] - Gross profit for the same period was RMB 481,000, reflecting a growth of 99.6% from RMB 241,000 in 2024[3] - The pre-tax loss narrowed slightly to RMB (208,984) from RMB (212,250), a decrease of 1.5% year-over-year[3] - The net loss attributable to ordinary equity holders of the parent was RMB (208,984), with a loss per share of RMB (2.08), an improvement from RMB (2.15) in 2024[3] - The company reported a total comprehensive loss of RMB (209,060) for the year, compared to RMB (212,147) in 2024[7] - Other income increased to RMB 2,420,000 in 2025 from RMB 1,827,000 in 2024, a growth of approximately 32.4%[19] - Financial costs decreased to RMB 1,236,000 in 2025 from RMB 6,009,000 in 2024, indicating improved financial management[22] - The company reported a basic loss per share of RMB 2.08 for 2025, compared to RMB 2.15 for 2024, reflecting a slight improvement in performance[29] - Losses decreased from RMB 212.2 million in 2024 to RMB 209.0 million in 2025, a reduction of RMB 3.2 million[59] Assets and Liabilities - Cash and cash equivalents surged by 354.2% to RMB 632,372 from RMB 139,213 in 2024[3] - Total assets less current liabilities increased significantly to RMB 647,072 from RMB 173,496 in 2024[9] - The company's total equity rose to RMB 624,583, up from RMB 150,535 in the previous year[9] - Non-current liabilities decreased slightly to RMB 22,489 from RMB 22,961 in 2024[9] - Current assets increased by 376.7% from RMB 125.6 million as of December 31, 2024, to RMB 598.7 million as of December 31, 2025, primarily due to net proceeds from the global offering[61] - The current ratio improved significantly from 8.3 in 2024 to 17.1 in 2025, indicating enhanced liquidity[60] Research and Development - Research and development expenses decreased by 2.1% to RMB 89,417 from RMB 91,326 in the previous year[3] - The company has developed a pipeline of ten candidate products, including two core PDGF products, Pro-101-1 and Pro-101-2, targeting various wound healing indications[38] - Pro-101-1 is currently preparing for Phase III clinical trials in China, while Pro-101-2 is in Phase II trials, showcasing the company's commitment to advancing its product pipeline[40] - The company is advancing its PDGF candidate products for nine additional indications in preclinical development[41] - The R&D team consists of professionals with an average of over 15 years of industry experience, focusing on drug development and innovation[48] - The company is committed to building an integrated R&D, production, and sales capability to accelerate the commercialization of core products[51] - The company is actively engaged in research related to mRNA and lncRNA, which are critical for its product development and innovation strategies[91] Capital and Funding - The total issued and fully paid capital increased to RMB 117,658,000 in 2025 from RMB 100,009,000 in 2024, reflecting successful capital raising efforts[36] - The net proceeds from the global offering were approximately HKD 599.8 million, expected to be utilized as outlined in the prospectus[71] - The company plans to allocate 61.8% of the net proceeds, amounting to HKD 370.7 million, for the ongoing clinical development and commercialization of core products Pro-101-1 and Pro-101-2 by the end of 2030[72] - 18.8% of the net proceeds, totaling HKD 112.8 million, is designated for purchasing professional equipment and instruments to enhance R&D capabilities by the end of 2028[72] - The company has allocated 10.0% of the net proceeds, equivalent to HKD 60.0 million, for working capital and general corporate purposes by the end of 2028[72] Corporate Governance and Compliance - The company is committed to high standards of corporate governance and has complied with all applicable code provisions since the listing date[79] - The audit firm Ernst & Young has confirmed that the financial data in the preliminary results announcement is consistent with the draft consolidated financial statements[78] - No significant litigation or arbitration has been reported during the reporting period, and there are no known pending or threatened significant lawsuits against the company as of December 31, 2025[74] Market Strategy and Future Plans - The company aims to become a leading global enterprise in the pharmaceutical industry by providing better treatment options for patients with skin injuries[37] - The company is exploring various administration routes for its PDGF candidates, including topical gels, sprays, eye drops, and oral formulations[40] - The company is focused on developing core products Pro-101-1 and Pro-101-2, which are PDGF-BB gels for clinical trials related to burn injuries and diabetic foot ulcers[87] - Approximately 25% of diabetes patients in China experience diabetic foot ulcers, indicating a significant market opportunity for the company's products[88] - The company is focused on expanding its market presence and exploring potential mergers and acquisitions to enhance its growth trajectory[88] - The company is exploring partnerships with contract research organizations (CROs) to enhance its research capabilities and expedite clinical trials[87] Administrative and Operational Expenses - Employee benefits expenses totaled RMB 119,050,000 in 2025, compared to RMB 120,621,000 in 2024[21] - Administrative expenses rose by 1.5% from RMB 116.8 million in 2024 to RMB 118.6 million in 2025, mainly due to expenses related to the listing process[55] - R&D expenses decreased by 2.1% from RMB 91.3 million in 2024 to RMB 89.4 million in 2025, attributed to a reduction in share-based payments and service fees related to CDMO and CRO services[56] - Capital expenditures amounted to RMB 3.2 million in 2025, down from RMB 14.1 million in 2024, primarily due to purchases of property, plant, and equipment[68]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 華芢生物科技（青島）股份有限公司 執行董事兼董事會主席 賈麗加女士 （股份代號：2396） 董事會會議召開日期 華芢生物科技（青島）股份有限公司（「本公司」），連同其附屬公司統稱「本集團」） 董事會（「董事會」）謹此宣佈，將於2026年3月30日（星期一）舉行董事會會議， 藉以（其中包括）考慮及通過本集團截至2025年12月31日止的年度業績及其發佈， 派發末期股息之建議（如有），以及處理其他事項。 承董事會命 B&K CORPORATION LIMITED 華芢生物科技（青島）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 中國，青島 2026年3月18日 於本公告日期，董事會包括(i)執行董事賈麗加女士、王軻瓏先生、翟俊輝博士及苗天祥先生； (ii)非執行董事林穎女士及袁飛先生；及(iii)獨立非執行董事霍志達先生、李嘉焱先生及岳儀 春先生。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 華芢生物科技（青島）股份有限公司 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02396 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 83,022,145 | RMB | | 1 RMB | | 83,022,145 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 83,022,145 | RMB | | 1 RMB | | 83,022,145 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 ( ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 B&K CORPORATION LIMITED 華芢生物科技（青島）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2396） 於2026年2月10日舉行的2026年第一次臨時股東大會 投票表決結果 茲提述華芢生物科技（青島）股份有限公司（「本公司」）刊發的日期均為2026年 1月26日的2026年第一次臨時股東大會通告（「臨時股東大會通告」）及通函（「通 函」）。除文義另有所指外，本公告所用的詞彙應與臨時股東大會通告及通函所 界定者具有相同涵義。 臨時股東大會投票表決結果 董事會宣佈，於2026年2月10日，臨時股東大會通告所載的擬議決議案已以投 票表決方式進行。臨時股東大會上提呈的所有決議案的投票表決結果如下： | | 普通決議案 | | （附註1） 投票數目(%) | | | --- | --- | --- | --- | --- | | | | 贊成 | 反對 | 棄權 | ...

致：香港交易及結算所有限公司 公司名稱: 華芢生物科技（青島）股份有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02396 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 83,022,145 | RMB | | 1 RMB | | 83,022,145 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 83,022,145 | RMB | | 1 RMB | | 83,022,145 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | ...

Group 1 - A total of 78 stocks reached a 52-week high as of February 3, with notable performers including Asia Pacific Financial Investments (08193) at 57.14%, Chao Wei Holdings (08059) at 36.00%, and Asia Backup (08290) at 33.33% [1] - The closing prices for the top three stocks that reached new highs were 0.550, 0.052, and 0.024 respectively, with their highest prices being 0.550, 0.068, and 0.036 [1] - Other significant stocks that reached new highs include Huameilele (08429) with a high rate of 20.37% and Haode Holdings (08149) at 17.65% [1] Group 2 - The report also lists stocks that reached 52-week lows, with the worst performer being Gaodi Holdings (01676) at -10.00%, followed by Huajian Medical (01931) at -9.29% and Electronic Trading Group (08036) at -9.09% [3] - The closing prices for the stocks that reached new lows include 0.340, 1.280, and 0.021 respectively, with their lowest prices being 0.315, 1.270, and 0.020 [3] - Other notable stocks that reached new lows include Controllon (01912) at -8.93% and Cool Link (08491) at -8.11% [3]

Core Viewpoint - The company announced the resignation of Mr. He Hongtian from multiple key positions due to personal matters, effective January 30, 2026, and the appointment of Ms. Zhang Liting and Ms. Qiu Haiyan to fill these roles [1] Group 1 - Mr. He Hongtian has resigned as co-secretary, financial director, board secretary, and vice president of the company [1] - Ms. Zhang Liting has been appointed as co-secretary of the company, effective January 30, 2026 [1] - Ms. Qiu Haiyan has been appointed as financial director, board secretary, and vice president, effective January 30, 2026 [1]

Core Viewpoint - The company announced significant changes in its executive team, with the resignation of Mr. He Hongtian and the appointment of Ms. Zhang Liting and Ms. Qiu Haiyan, effective January 30, 2026 [1] Group 1 - Mr. He Hongtian has resigned from his positions as co-secretary, financial director, board secretary, and vice president due to personal matters [1] - Ms. Zhang Liting has been appointed as co-secretary of the company [1] - Ms. Qiu Haiyan has been appointed as financial director, board secretary, and vice president [1]

Core Viewpoint - Huazhong Bio-B (02396.HK) announced the resignation of He Hongtian from multiple positions including co-secretary, CFO, board secretary, and vice president effective January 30, 2026 [1] Management Changes - He Hongtian resigned due to personal reasons, and his departure will take effect on January 30, 2026 [1] - Zhang Liting has been appointed as co-secretary, and Qiu Haiyan has been appointed as CFO, board secretary, and vice president, both effective January 30, 2026 [1] - Huang Huier will continue to serve as another co-secretary [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 B&K CORPORATION LIMITED 華芢生物科技（青島）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2396） 更換聯席公司秘書、 財務總監、董事會秘書及副總裁； 以及獲豁免嚴格遵守上市規則第3.28及8.17條 更換聯席公司秘書、財務總監、董事會秘書及副總裁 華芢生物科技（青島）股份有限公司（「本公司」，連同其附屬公司統稱「本集團」） 董事（「董事」）會（「董事會」）謹此宣佈，何鴻添先生（「何先生」）已因個人事務 而辭任本公司聯席公司秘書（「聯席公司秘書」）、財務總監（「財務總監」）、董事 會秘書（「董事會秘書」）及副總裁，自2026年1月30日起生效。 何先生已確認其與董事會並無意見分歧，亦無其他事宜須敦請本公司股東或 香港聯合交易所有限公司（「聯交所」）垂注。 董事會進一步宣佈，於何先生辭任聯席公司秘書、財務總監、董事會秘書及副 總裁後，張麗婷女士（「張女士」） ...